Christopher M. Counter,Kian-Huat Lim,Brooke B. Ancrile,David F. Kashatus
申请号：
US12863600
公开号：
US08927598B2
申请日:
2009.01.09
申请国别(地区):
US
年份:
2015
代理人:
摘要：
Oncogenic Ras-driven cancer is treated with agent by interrupting pathway comprising activation of Akt by oncogenic Ras, activated Akt causing phosphorylation of eNOS at S1177 site of eNOS to provide activated eNOS in cancer cells and activated eNOS causing activation of wildtype Ras by nitrosylation thereof at C118 to provide GTP-bound activated wildtype H and N Ras. L-NAME can be orally administered to interrupt this pathway. Wortmannin can be administered intravenously to interrupt this pathway. Novel siRNAs are disclosed useful to interrupt said pathway.
